Physician profile
Mark E Jackson
NPI 1275536013
$1,078.17
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $624 · 2022: $312 · 2023: $83.36 · 2024: $58.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $194.97 | 2021-2022 | |
| Abbvie INC. | $163.19 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $145.85 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.74 | 2021-2022 | |
| Amgen INC. | $86.91 | 2021-2024 | Prolia, Evenity |
| Lilly USA, LLC | $64.47 | 2021-2022 | |
| Astellas Pharma US INC | $44.03 | 2021-2022 | |
| Novo Nordisk INC | $41.51 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $31.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.52 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.12 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.02 | 2021 | |
| Eisai INC. | $19.75 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.68 | 2023 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $13.34 | 2024 | Cologuard Collection Kit |
| Radius Health, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.